Methotrexate shows promise for treating juvenile scleroderma

01/8/2013 | PhysiciansBriefing.com

More than 70% of juvenile localized scleroderma patients who took oral methotrexate were in clinical remission for a mean of 25 months, while 27.1% experienced remission while taking the drug, according to an Italian study in the Journal of the American Academy of Dermatology. Generally mild side effects were reported by 48.3% of respondents, but they didn't cause the patients to stop the medication.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA